Koers Stellar Biotechnologies Inc Toronto S.E.
Aandelen
KLH
CA85855A2039
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 13,69 mln. 18,69 mln. 12,61 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -8 mln. -10,92 mln. -7,37 mln. | Nettowinst (verlies) 2025 * | -10 mln. -13,65 mln. -9,21 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-1,88
x | K/w-verhouding 2025 * |
-2,56
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 71,55% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Pardeep Nijhawan
FOU | Founder | 53 | 12-06-07 |
Michael Brooks
PSD | President | 46 | 01-09-15 |
Stephen Lemieux
DFI | Director of Finance/CFO | 48 | 15-07-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sean MacDonald
BRD | Director/Board Member | 47 | 07-06-19 |
Frank Oakes
BRD | Director/Board Member | 73 | 09-04-10 |
Patrick Marshall
BRD | Director/Board Member | 53 | 23-05-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,83% | 115 mld. | |
+10,80% | 105 mld. | |
-10,84% | 22,71 mld. | |
-0,70% | 21,83 mld. | |
-10,37% | 18,18 mld. | |
-41,92% | 16,52 mld. | |
-15,11% | 16,01 mld. | |
+6,62% | 14,14 mld. | |
+17,53% | 10,71 mld. |